Islet Sciences, Inc. to Present at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014
RALEIGH, N.C., June 18, 2014 /PRNewswire/ -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, will present a peer-reviewed poster relating to its highly selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.
The poster describes positive preclinical efficacy results for remogliflozin etabonate in two models of non-alcoholic steatohepatitis (NASH), a serious condition that resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. NASH can cause severe scarring of the liver leading to the development of cirrhosis and other serious complications. Currently, no specific therapies for NASH exist.
The etiology of NASH is not certain, but the combination of insulin resistance and oxidative stress has been shown to be important hallmarks of the disease. Previous findings, including those from two Phase 2b clinical studies, showed that remogliflozin etabonate is able to increase insulin sensitivity in type 2 diabetic patients, and the differentiated chemical structure of remogliflozin confers increased antioxidant properties compared to other SGLT2 inhibitors. These characteristics make remogliflozin etabonate a unique and promising potential therapy for treating NASH.
The poster will be available for viewing in Hall F on Saturday, June 21, from 1:00pm to 3:00pm Central Time. The poster is summarized below:
Title: Remogliflozin Etabonate Improves Non-Alcoholic Steatohepatitis
Authors: William Wilkison, PhD1; Benjamin M Buehrer2; Bentley Cheatham3; Susan Walker3; Shigeru Nakano4; Kenji Katsuno4; Masayuki Isaji4
1Islet Sciences, Inc., Raleigh, NC; 2Zen-Bio Inc., Research Triangle Park, NC; 3BHV Pharma, Research Triangle Park, NC; 4Kissei Pharmaceuticals, Matsumoto City, Japan
BHV Pharma owns exclusive rights to remogliflozin in the global territory outside of Japan, Korea and Taiwan, through a license from Kissei Pharmaceuticals.
About Islet Sciences
Islet Sciences, Inc., a biopharmaceutical company based in Raleigh, NC, is developing new medicines and technologies for the treatment and diagnosis of metabolic disease. On March 13, 2014, the Company announced the execution of a binding letter of intent to acquire BHV Pharma. The combined pipeline includes remogliflozin etabonate for the treatment of type II diabetes and NASH, a cell-based transplantation therapy for insulin-dependent diabetes; first-in-class immune-modulating small molecule IL-12 inhibitors targeting beta-cell preservation, and a PCR-based molecular diagnostic measuring beta-cell loss for the diagnosis of type 1 diabetes or onset of insulin dependent type 2 diabetes. For more information, please visit http://www.isletsciences.com.
About Kissei Pharmaceutical
Kissei Pharmaceutical Co., Ltd. was founded in 1946 and has grown into one of Japan's leading pharmaceutical companies. Kissei's management vision is to be an R&D-oriented pharmaceutical company that contributes to the health of people around the world through developing and commercializing innovative drugs. Kissei is actively pursuing collaborations with many companies to strengthen its R&D pipeline, and also promoting global expansion by licensing out original agents as an important management strategy. Kissei ranks metabolism & endocrinology as one of its major R&D areas and is putting significant effort into the development of novel therapeutic agents. For more information on Kissei, please see the international website http://www.kissei.co.jp/.
This press release contains forward-looking statements. Forward-looking statements for Islet Sciences, Inc. reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science, Inc.'s reports filed with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of the Company's control.
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
email@example.com; (212) 375-2664
Amy Wheeler (Media)
firstname.lastname@example.org; (646) 362-5750
SOURCE Islet Sciences, Inc.